ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 019

Developing Standard Improvement Curves for Disease Activity, Pain and Quality of Life in Children with Newly Diagnosed Juvenile Idiopathic Arthritis: Results from the CAPRI Registry

Amieleena Chhabra1, Matt Berkiwitz2, Thomas Loughin2, Lori Tucker3, Giles Boire4, Karine Toupin-April5, Dax Rumsey6, Michelle Batthish7, Linda Li8, Adam Huber9, Brian Feldman10, Jean-Phillippe Proulx-Gauthier11, Ciaran Duffy12, Paul Dancey13, Gordon Soon14, Heinrike Schmeling6 and Jaime Guzman15, 1University of British Columbia, Vancouver, BC, Canada, 2Simon Fraser University, Burnaby, BC, Canada, 3BC Children's Hospital, Vancouver, BC, Canada, 4Sherbrooke University, Sherbrooke, QC, Canada, 5University of ottawa, Ottawa, ON, 6University of Alberta, Edmonton, AB, Canada, 7McMaster Children's Hospital, Hamilton, ON, Canada, 8Arthritis research, Vancouver, BC, Canada, 9University of Nova Scotia, Halifax, NS, Canada, 10Hospital for Sick Children / University of Toronto, Toronto, ON, Canada, 11Université Laval, Québec, QC, Canada, 12Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, 13Université de Montréal, Montreal, QC, Canada, 14University of Toronto, Toronto, ON, 15University of British Columbia, Vancouver, BC

Meeting: 2023 Pediatric Rheumatology Symposium

Keywords: Juvenile idiopathic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Thursday, March 30, 2023

Title: Poster Breakout 2 - JIA & Uveitis: Genetics, Clinical & Therapeutic Aspects

Session Type: Breakout Session

Session Time: 5:10PM-5:40PM

Background/Purpose: When a diagnosis of juvenile idiopathic arthritis (JIA) is made, many parents are shocked to find out that arthritis occurs in children and may have concerns that arthritis is an incurable disease leading to inexorable deformities and disability. We know from research in the last 20 years that this is not the case for most, as the prognosis of JIA has improved substantially. But how do we convey this to families in an understandable and helpful way? We propose to use the analogy of growth charts and developed standard improvement curves of expected treatment-related improvements during the first year on pain, quality of life, and disease activity in children with JIA.

Methods: Data from the Canadian Alliance of Pediatric Rheumatology Investigators JIA Registry was used. Patients newly diagnosed with JIA were recruited from February 2017 to December 2021 (N=721) and followed as clinically indicated. At each clinic visit, self-reported pain intensity, Quality of My Life (QoML), and physician and parent global assessments were recorded in numerical rating scales from 0 to 10. The clinical Juvenile Arthritis Disease Activity Score 10 (cJADAS10) was the sum of physician and parent global, and the number of active joints up to 10.

Results: After assessing several parametric and non-parametric methods, Quantile Random Forests and LOWESS smoothing were used to chart the course of the 10th, 25th, 50th, 75th and 90th centiles for each measure during the first year after diagnosis and treatment initiation. A total of 721 children were recruited a median of 2 weeks after diagnosis, 61% were female and 44.5% had oligoarthritis (Table 1). During the first two years after diagnosis, there were a total of 3,671 visits that were used for plotting the charts. Using two years of data to produce curves for the first year improved their accuracy. During the first year, the 50th centiles changed from 3.5 to 1 for pain, from 3.5 to 1 for QoML, from 3 to 1 for the active joint count, and from 8 to 2 for the cJADAS10. The Figures provide examples of the resulting Charts.

Conclusion: Using real clinic data from Canadian children diagnosed with JIA in 2017-2021, we have produced standard curves of expected improvements during the first year after diagnosis that can be used to track individual childs progress and display for families how their child is doing in comparison to other children with JIA. These JIA Improvement Charts may assist families and physicians in making treatment decisions for the child. They may also help detect when early treatment adjustments are needed if improvement is faltering, in order to prevent long term damage.

Supporting image 1Table 1: Baseline characteristics of included patients

Supporting image 2Standard improvement curves for the 10th, 25th, 75th and 90th centiles in pain intensity during the first year after JIA diagnosis

Supporting image 3Standard improvement curves for the 10th, 25th, 50th, 75th and 90th centiles in CJADAS10 scores during the first year after JIA diagnosis.


Disclosures: A. Chhabra: None; M. Berkiwitz: None; T. Loughin: None; L. Tucker: None; G. Boire: None; K. Toupin-April: None; D. Rumsey: None; M. Batthish: AbbVie/Abbott, 5, Novartis, 6, Viatris, 12, AdBoard; L. Li: None; A. Huber: None; B. Feldman: None; J. Proulx-Gauthier: None; C. Duffy: None; P. Dancey: None; G. Soon: None; H. Schmeling: None; J. Guzman: None.

To cite this abstract in AMA style:

Chhabra A, Berkiwitz M, Loughin T, Tucker L, Boire G, Toupin-April K, Rumsey D, Batthish M, Li L, Huber A, Feldman B, Proulx-Gauthier J, Duffy C, Dancey P, Soon G, Schmeling H, Guzman J. Developing Standard Improvement Curves for Disease Activity, Pain and Quality of Life in Children with Newly Diagnosed Juvenile Idiopathic Arthritis: Results from the CAPRI Registry [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 4). https://acrabstracts.org/abstract/developing-standard-improvement-curves-for-disease-activity-pain-and-quality-of-life-in-children-with-newly-diagnosed-juvenile-idiopathic-arthritis-results-from-the-capri-registry/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2023 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/developing-standard-improvement-curves-for-disease-activity-pain-and-quality-of-life-in-children-with-newly-diagnosed-juvenile-idiopathic-arthritis-results-from-the-capri-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology